Apr 15, 2020 · Isocitrate dehydrogenase (IDH) enzymes catalyse the oxidative decarboxylation of isocitrate and therefore play key roles in the Krebs cycle and cellular homoeostasis.

Feb 8, 2025 · Explore how IDH mutations influence glioma development, impact prognosis, and guide diagnostic and therapeutic strategies. Isocitrate dehydrogenase (IDH) mutations are a key focus in glioma research due to their impact on tumor behavior and patient outcomes.

Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are essential metabolic enzymes involved in the tricarboxylic acid (TCA) cycle. Several mutations in IDH genes have recently been described in many solid tumors, including glioma, cholangiocarcinoma, and chondrosarcoma.

3 days ago · Spindle cell hemangioma: 64% (18/28) of the spindle cell hemangioma cases had IDH1 R132C mutation, with or without association with Maffucci syndrome; 2/28 had IDH2 R172T or IDH2 R172M mutations (Am J Pathol 2013;182:1494)

Our study highlights the differentiating potential of IDHi on the cellular hierarchies that drive oligodendrogliomas and suggests a genetic modifier that may improve patient stratification.

Mutant IDH proteins acquire a neomorphic enzyme activity to produce the putative oncometabolite D-2-hydroxyglutarate, which is thought to block cellular differentiation by competitively inhibiting α-ketoglutarate-dependent dioxygenases involved in histone and DNA demethylation.

Jun 15, 2021 · Mutations in IDH1 or IDH2 are frequent among several cancer types with various tissues of origin; the resultant mutated enzymes have neomorphic activity that leads to production of the...

Nov 21, 2024 · To characterize their malignant cell hierarchy, we profiled chromatin accessibility and gene expression across single cells from low-grade and high-grade IDH-mutant gliomas and ascertained...

Sep 10, 2024 · Malignant transformation (MT) is commonly seen in IDH-mutant gliomas. There has been a growing research interest in revealing its underlying mechanisms and intervening prior to MT at the early stages of the transforming process.

The IDH1 isogenic cell lines can be used for discovering new therapeutic targets. Advantages. Expresses the mutant IDH R132H, the most common hotspot mutation in gliomas; Both heterozygous and homozygous IDH R132H cell lines are available